New York-based Delcath’s offering includes nearly 1.7 million shares of its common stock at a public offering price of $13.25 per share, bringing the gross proceeds before deductions to approximately $22.2 million, according to a news release.
The interventional oncology company plans to put the proceeds toward the completion of its Focus clinical trial for patients with hepatic dominant ocular melanoma as well as the preparation for the regulatory process for its Hepzato kit for high-dose chemotherapy to the liver.
Additionally, the company will put some funds toward the commercial launch of Hepzato, further clinical developments and other general corporate purposes. Delcath closed the offering on Dec. 11.
Canaccord Genuity and Roth Capital Partners acted as joint book-running managers for the proposed offering.